Thermo Fisher Acquires Henogen S.A.
To accelerate demand for cell and gene vaccines and therapies globally, Thermo Fisher and Groupe Novasep SAS (Novasep) announced that Thermo Fisher has acquired Henogen S.A., Novasep’s viral vector manufacturing business in Belgium. With two locations in Seneffe and Gosselies, Belgium, Novasep’s viral vector business has more than 7,000 m2 of state-of-the-art clinical and commercial manufacturing capacity and approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes.
Learn More »
Thermo Fisher to Expand Plasmid DNA Manufacturing
To accelerate commercialization of plasmid-based medicines and vaccines, Thermo Fisher is constructing a new cGMP plasmid DNA manufacturing facility in Carlsbad, CA. The new site will expand the company’’s clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies including life-saving cancer treatments and mRNA vaccines. The site will also have the capability to produce large-scale plasmid DNA as a primary drug substance for DNA therapies.
Learn More »
Thermo Fisher Expands Clinical Supply Chain Services in Europe
To meet accelerating demand for robust clinical supply chain services throughout Europe, Thermo Fisher has expanded its pharma services footprint with two new state-of-the-art facilities in Rheinfelden and Weil am Rhein, Germany. The new sites will bring much-needed clinical supply chain continuity and specialized cold chain and cryogenic expertise across Europe and globally. These new facilities feature innovative and highly automated technologies to optimize efficiency and quality across the pharma services supply chain.
Learn More »
Thermo Fisher to Expand Global Steriles in North America and Europe
To meet the rapidly growing global demand for injectable sterile drugs, Thermo Fisher is further expanding its pharma services footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines. Over the next two years, expansion projects at our sites in Greenville, NC, Ferentino and Monza, Italy, and Swindon, UK, will add 15 development and commercial production lines to support a range of capabilities, including live virus, aseptic liquid and lyophilized vial filling, to further enhance our global steriles network.
Learn More »
Thermo Fisher and Innoforce Announce a Joint Venture to Establish New Biologics and Sterile Drug Manufacturing Facility in China
To meet the increasing demand globally and bring expertise and capacity for global customers seeking capabilities to bring novel medicines to patients, Thermo Fisher and Innoforce, a bioinnovation-enabling company, have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles development and manufacturing. The joint venture expands our pharma services network for customers of all sizes both in China and outside of China.
Learn More »
Dr. Richard Snyder, Vice President, Science & Technology Named 2020 Innovator of the Year
We’re excited to announce our own Dr. Richard Snyder, Vice President, Science & Technology has been named the 2020 Innovator of the Year by University of Florida UF Innovate. His contributions to therapeutic gene therapy have helped patients around the world.
Learn More »
Thermo Fisher Announces Plans to Expand Sterile Filling Capacity for Vaccines and Therapies with New Facility in Singapore
To enhance our support for global health and preparedness in the Asia-Pacific region, Thermo Fisher announced plans to develop two new sterile filling lines in Singapore to extend capacity to the region for the development and manufacture of therapies and vaccines. Established with Singapore Economic Development Board (EDB) support, the new facility, operated by Thermo Fisher, will have the capability to manufacture pharmaceutical products to meet the demand in the region and respond effectively to health emergencies.
Learn More »
